HIMS:NYE-Hims Hers Health Inc (USD)

COMMON STOCK | Household & Personal Products |

Last Closing

USD 26.56

Change

0.00 (0.00)%

Market Cap

USD 7.48B

Volume

8.87M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-28 )

Largest Industry Peers for Household & Personal Products

Symbol Name Price(Change) Market Cap
UL Unilever PLC ADR

N/A

USD 142.38B
KMB Kimberly-Clark Corporation

N/A

USD 43.79B
CHD Church & Dwight Company Inc

N/A

USD 25.99B
CLX The Clorox Company

N/A

USD 20.35B
ELF ELF Beauty Inc

N/A

USD 7.25B
COTY Coty Inc

N/A

USD 6.12B
SPB Spectrum Brands Holdings Inc

N/A

USD 2.40B
EPC Edgewell Personal Care Co

N/A

USD 1.66B
PZC PIMCO California Municipal Inc..

N/A

USD 0.63B
YSG Yatsen Holding

N/A

USD 0.47B

ETFs Containing HIMS

EDOC:AU BetaShares Digital Health.. 6.74 % 0.00 %

N/A

N/A
DDOC:XETRA Global X Telemedicine & D.. 5.68 % 0.00 %

N/A

USD 5.39M
DDOC:F Global X Telemedicine & D.. 5.68 % 0.00 %

N/A

USD 4.62M
FDOC:LSE Fidelity Digital Health U.. 4.93 % 0.00 %

N/A

USD 3.18M
EDOC:LSE Global X Telemedicine & D.. 4.66 % 0.00 %

N/A

USD 2.18M
EDOG:LSE Global X Telemedicine & D.. 4.66 % 0.00 %

N/A

USD 0.48M
EDOC:SW Global X Telemedicine & D.. 4.40 % 0.00 %

N/A

N/A
XHS SPDR® S&P Health Care Se.. 3.80 % 0.35 %

N/A

USD 0.07B
PSCH Invesco S&P SmallCap Heal.. 3.48 % 0.29 %

N/A

USD 0.18B
QSML WisdomTree U.S. SmallCap .. 0.84 % 0.00 %

N/A

USD 8.03M
FNX First Trust Mid Cap Core .. 0.45 % 0.62 %

N/A

USD 1.26B
FFTY Innovator IBD® 50 ETF 0.00 % 0.80 %

N/A

N/A
FNY First Trust Mid Cap Growt.. 0.00 % 0.70 %

N/A

USD 0.40B
IJS iShares S&P Small-Cap 600.. 0.00 % 0.25 %

N/A

USD 7.70B
IBUY Amplify Online Retail ETF 0.00 % 0.65 %

N/A

USD 0.18B
RTWO:LSE L&G Russell 2000 US Small.. 0.00 % 0.00 %

N/A

USD 0.23B
RTWP:LSE Legal & General UCITS ETF.. 0.00 % 0.00 %

N/A

USD 0.23B
ETLZ:XETRA L&G Russell 2000 US Small.. 0.00 % 0.00 %

N/A

USD 0.09B
EDOC Global X Telemedicine & D.. 0.00 % 0.00 %

N/A

USD 0.04B

Market Performance

  Market Performance vs. Industry/Classification (Household & Personal Products) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 198.43% 100% F 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 198.43% 100% F 99% N/A
Trailing 12 Months  
Capital Gain 198.43% 100% F 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 198.43% 100% F 99% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 36.32% 89% A- 90% A-
Dividend Return 36.32% 89% A- 89% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 80.84% 11% F 11% F
Risk Adjusted Return 44.93% 72% C 59% D-
Market Capitalization 7.48B 69% C- 82% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.